The Claim
In adults with MASLD without type 2 diabetes, withdrawal of liraglutide therapy is associated with increased expression of four adipose tissue genes (including CAMK2B) compared to withdrawal of lifestyle intervention, indicating a pharmacologically mediated disruption of adipose tissue regulation contributing to metabolic rebound.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
When adults with MASLD but without type 2 diabetes stop taking liraglutide, four specific genes in fat tissue increase in activity, a change not seen when they stop lifestyle changes, indicating that liraglutide withdrawal uniquely alters fat tissue regulation in a way that contributes to metabolic rebound.
See the scientific wording
In adults with MASLD without type 2 diabetes, withdrawal of liraglutide therapy is associated with increased expression of four adipose tissue genes (including CAMK2B) not observed after lifestyle withdrawal, suggesting a pharmacologically mediated disruption of adipose tissue regulation that may contribute to metabolic rebound.
When the drug stops working, fat cells suddenly change how they behave, turning on genes that make them less sensitive to insulin and release inflammatory signals into the blood. This causes the body to store more fat and burn less energy, leading to rapid weight gain.
What the research says
1 studyWhen people with fatty liver stop taking liraglutide, their fat tissue starts acting strangely in ways that don’t happen when they stop dieting — this might explain why they gain weight back faster after stopping the drug.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.